Enhanced Fault Detection and Correction for Microneedle Array-Based Continuous Analyte Monitoring Devices

This inventive concept introduces advanced fault detection and correction mechanisms to improve the reliability and accuracy of microneedle array-based continuous analyte monitoring devices, enhancing patient safety and device performance.

The original patent, 'Fault detection for microneedle array based continuous analyte monitoring device', addresses the critical need for reliable analyte monitoring in diabetes management. However, it has limitations in detecting and responding to sensor faults, which can lead to inaccurate readings and compromised patient safety. This new inventive concept addresses these limitations by incorporating advanced fault detection, isolation, and correction mechanisms to ensure uninterrupted and accurate analyte monitoring.

The new inventive concept comprises a fault detection system that utilizes sensor data analysis and machine learning-based anomaly detection to identify faulty sensors. The system triggers a recalibration of the sensor array or replaces faulty sensors with redundant sensors to maintain accurate analyte monitoring. Additionally, the concept includes a fault-tolerant microneedle array-based continuous analyte monitoring device with built-in redundancy, dynamic sensor operation adjustment, and real-time fault detection and correction capabilities.

The new claims introduce novel fault detection and correction mechanisms that significantly improve the reliability and accuracy of microneedle array-based continuous analyte monitoring devices. The inventive step lies in the integration of advanced fault detection algorithms, machine learning-based anomaly detection, and redundant sensor arrays to ensure uninterrupted and accurate analyte monitoring.

Alternative embodiments of the inventive concept could include the use of different sensor materials, varying sensor array configurations, or the integration of additional fault detection mechanisms, such as electrical impedance spectroscopy or optical sensing. Variations could also involve adapting the concept to monitor different analytes or using it in conjunction with other medical devices.

The enhanced fault detection and correction mechanisms have significant commercial potential in the continuous glucose monitoring market, where accuracy and reliability are critical. The inventive concept can be integrated into existing devices or used in the development of new products, providing a competitive advantage in the market. Target industries include medical device manufacturers, healthcare providers, and pharmaceutical companies.